Latest Headlines
PR Newswire
Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)
7 小时前
PR Newswire
FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
7 小时前
PR Newswire
Yiwu Global Digital Trade Center Opens, Setting Worldwide Digital Commerce Benchmark
7 小时前
It's better on the app

👈 Scan the QR code to download